IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: In trial No 2, the aim is to investigate whether patients with chronic-phase chronic myeloid leukemia who have achieved a CCyR) on imatinib or nilotinib can then be treated with a combination of the tyrosine kinase inhibitor and peg-IFN-α for 2 years.